Company / R&D Expense
Arrowhead Pharmaceuticals R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$607.2M
FY2025
5-year range
$128.9M / $607.2M
FY2021-FY2025
Trend
+20.0%
vs FY2024
Sector context
#30 of 210
Health Care
What the data says
Arrowhead Pharmaceuticals's r&d expense of $607M is higher than 86% of companies in the Health Care sector (FY2025). R&D Expense has increased for 3 consecutive years, from $129M in FY2022 to $607M in FY2025.
Based on SEC 10-K filings.
$607M in FY2025 with a 5-year CAGR of +36.3%. Top quartile in the Health Care sector.
Improved from $206M to $607M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +67.6%
- 5-Year CAGR
- +36.3%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 210This company $607.2M Sector average $644.1M
▼
-5.7% below sector average
Key checks
Key Insights
- Arrowhead Pharmaceuticals's r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +36.3%, indicating consistent growth.
- In FY2025, r&d expense increased 20.0% year-over-year.
- Ranks #30 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $607.2M | +20.0% |
| FY2024 | $505.9M | +145.2% |
| FY2023 | $206.3M | +60.1% |
| FY2022 | $128.9M | -37.5% |
| FY2021 | $206.3M | +60.1% |
| FY2020 | $128.9M | +153.2% |
| FY2019 | $50.9M | -18.1% |
| FY2018 | $62.1M | +31.4% |
| FY2017 | $47.3M | -23.9% |
| FY2016 | $62.1M | +613.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026